Home » Eisai Signs Pact With GSK
Eisai Signs Pact With GSK
Signaling the entry of the Japanese into the Indian pharmaceutical sector, Eisai Pharmaceuticals India, a 100 percent subsidiary of Eisai of Japan, announced the signing of a co-promotion agreement with GlaxoSmithKline Pharmaceuticals (GSK) for Paritec in India. Paritec is a proton pump inhibitor (PPI) with the molecule being rabeprazole and was discovered and developed by Eisai Co. and is approved for the treatment of acid-related disorders such as peptic ulcer and reflux gastric disorders (GERD).
()a href="http://www.hindu.com/2005/05/27/stories/2005052701821700.htm" target="_blank">The Hindu
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May